FDA Approves First New Treatment for Mesothelioma in 15 Years
The U.S. Food & Drug Administration on Thursday approved Tumor Treating Fields, a therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth, for the first-line treatment of malignant pleural mesothelioma. It is the first treatment in more than 15 years that the FDA approves for mesothelioma. In 2004, the agency added the chemotherapy drug pemetrexed (Alimta) to standard-of-care treatment. The FDA approved Novocure’s NovoTTF-100L System under the agency’s Humanitarian Device Exemption. The approval comes eight months after Novocure, which manufactures and markets the dev...
Source: Asbestos and Mesothelioma News - May 24, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Quality of Life Still Good with HIPEC Surgery for Peritoneal Mesothelioma
This study shows that the improvement in quality of life can be very significant compared with the preoperative status,” Levine said. “By six months, virtually all of the patients had recovered to preoperative baseline or better quality-of-life measures.” The post Quality of Life Still Good with HIPEC Surgery for Peritoneal Mesothelioma appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - May 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Clinical Trial Exploring Family Predisposition
The National Cancer Institute has opened a clinical trial using mesothelioma patients and their family members to explore predisposition to the cancer and potential solutions to negating it. The trial is a follow up to an earlier study of a genetic mutation that creates susceptibility to various cancers but a longer-than-normal survival with platinum-based chemotherapy treatment. “This is an important, long-term study that could have implications not only for a patient, but for family members, too,” Dr. Raffit Hassan, NCI senior investigator told The Mesothelioma Center at Asbestos.com. “Progress can be m...
Source: Asbestos and Mesothelioma News - May 20, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Latest T-Cell Study Opens for Mesothelioma Patients
Sarah Cannon Research Institute in Nashville, Tennessee, and MD Anderson Cancer Center in Houston have opened a much-anticipated clinical trial involving a novel T-cell therapy for patients with mesothelioma. The two institutions are establishing dosage levels and measuring efficacy of TC-210, a type of immunotherapy that targets mesothelin, a cell surface protein highly expressed in several cancers. The study also is open to patients with certain types of bile duct, ovarian and non-small cell lung cancer. Participation is based upon individual levels of mesothelin expression. Researchers at the two centers are hoping to ...
Source: Asbestos and Mesothelioma News - May 16, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Radiotherapy Can Double Two-Year Survival for Mesothelioma
A novel radiotherapy regimen can double the chances of surviving two or more years with pleural mesothelioma, according to Dr. Marco Trovo at University Hospital of Udine in Italy. Trovo is the lead author of a study involving 108 patients treated for malignant mesothelioma between 2014 and 2018 at the National Cancer Institute in Aviano, Italy. He presented the findings this week at the annual European Society for Therapeutic Radiology and Oncology convention in Milan. “Radiotherapy has evolved dramatically in the last few years, so we wanted to see if it could now be used to prevent cancer from spreading to nearby ...
Source: Asbestos and Mesothelioma News - May 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study: Elderly Mesothelioma Patients Denied Valuable Survival Time
Almost two-thirds of the elderly patients being diagnosed with mesothelioma are dying without receiving any cancer-related treatment that could significantly extend survival. Median survival is just 4.1 months, according to the first extensive study of mesothelioma patients 80 years or older. The Annals of Surgical Oncology published the recent study, authored by mesothelioma specialists at five highly rated medical facilities. “Too many elderly patients are being denied valuable survival time,” Dr. Charles B. Simone II, chief medical officer at the New York Proton Center and co-author of the study, told The M...
Source: Asbestos and Mesothelioma News - May 13, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

EPA Ignored Advice from Staff Experts When Issuing New Asbestos Rule
More than a dozen senior officials and experts at the Environmental Protection Agency urged the EPA to ban asbestos outright, a new report shows. Two internal memos obtained by the Asbestos Disease Awareness Organization and shared with the New York Times reveal the EPA’s own scientists and lawyers advised the agency to issue a complete ban of asbestos instead of the recent regulations that only restricted its domestic use. In the memos, dated Aug. 10, 2018, EPA staff members wrote that the agency “should seek to ban all new uses of asbestos because the extreme harm from this chemical substance outweighs any ...
Source: Asbestos and Mesothelioma News - May 8, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Novel Imaging May Make Peritoneal Mesothelioma Surgery More Effective
Dr. James Cusack at Massachusetts General Hospital has begun using a novel imaging system for patients with peritoneal mesothelioma that could better identify tumor cells during surgery, reducing the chance of recurrence. Cusack, an associate professor of surgery at the Harvard University Medical School, is also studying the molecular imaging technology with select cases of appendiceal, ovarian and gastrointestinal cancers. The single-center clinical trial, which started April 3, aims to determine safety and efficacy of the procedure for peritoneum metastases, according to Cusack. The Lumicell System already has been studi...
Source: Asbestos and Mesothelioma News - May 6, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

NIOSH Asking for National Mesothelioma Registry Input
The National Institute for Occupational Safety and Health has begun soliciting public input on the feasibility of establishing a mesothelioma registry. NIOSH is encouraging doctors, nurses, patients, families and patient advocates to provide recommendations on data collection, enrollment, registry maintenance, confidentiality and the overall usefulness of such a tool if enacted. Comments must be received by July 8, 2019. “NIOSH has a strong interest in preventing mesothelioma and helping people with the disease,” according to its outreach effort on Regulations.gov. “Mesothelioma treatments are limited, an...
Source: Asbestos and Mesothelioma News - May 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Optimism High for Mesothelioma Immunotherapy Clinical Trial in Europe
A novel clinical trial aiming to train the immune system to recognize and attack pleural mesothelioma tumor cells has opened with considerable optimism across five European countries. The randomized phase II/III study is designed to measure the efficacy and anti-tumor activity of MesoPher, a vaccine combining a patient’s own dendritic immune cells with a specially engineered cell line. The multicenter study, which is hoping for 235 participants, has opened in Antwerp, Belgium; Lille, France; Ancona, Italy; Amsterdam and Rotterdam, Netherlands and Leicester, England. “There is hope, a lot of hope, with this stud...
Source: Asbestos and Mesothelioma News - April 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

EPA ’s Latest Asbestos Regulation Falls Short of Full Ban
The Environmental Protection Agency issued a new regulation on Wednesday that will make it tougher to domestically manufacture, import or sell products made with asbestos, the toxic mineral that causes mesothelioma and other diseases. The regulation closes a loophole in the partial ban of asbestos that was legislated almost 30 years ago. It will strengthen the EPA’s ability to review and prohibit the use of a long list of asbestos products that are not banned but have been long abandoned by the industry. The ruling is part of a legislative process that requires the EPA to review its regulation of asbestos under the...
Source: Asbestos and Mesothelioma News - April 18, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

EPA Removes Part of Libby Asbestos Cleanup from Superfund List
The U.S. Environmental Protection Agency has deleted a 45-acre portion of the Libby Asbestos Superfund site from the National Priorities List. The EPA and the Montana Department of Environmental Quality have agreed that institutional controls to prevent any future exposure to asbestos in the area were satisfied. It’s a step closer to finishing the decontamination of the longest-running, man-made environmental disaster in American history. The sprawling Superfund site, which was placed on the National Priorities List in 2002, was originally divided into eight operable units. The units were based upon the extent of co...
Source: Asbestos and Mesothelioma News - April 16, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Cancer-Related Insomnia: New Research Finds Effective Treatments
This study was a first of its kind. It involved a head-to-head comparison of acupuncture and cognitive behavioral therapy, enrolled patients with many different types of cancer and included nearly 30% minority participants. Previous studies focused solely on breast cancer and included 90% white participants. Limitations of the previous research make it difficult to determine if the results are applicable to patients with other cancers and people of diverse backgrounds. Cognitive Behavioral Therapy and Acupuncture Are Effective Acupuncture and cognitive behavioral therapy treatments produced clinically meaningful reduction...
Source: Asbestos and Mesothelioma News - April 15, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

CAR T-Cell Therapy for Mesothelioma Proving Effective in Clinical Trial
Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center believes novel CAR T-cell therapy will be part of future, standard-of-care treatment for malignant pleural mesothelioma. The therapy involves the laboratory reprograming of a patient’s T cells — a type of white blood cell — to attack the cancer by targeting mesothelin, a surface protein. CAR T-cell therapy is a form of immunotherapy that could extend mesothelioma survival significantly. “That’s my goal. That’s what we’ve been working toward for many years,” Adusumilli told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - April 11, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Gene Therapy Trial for Mesothelioma Opens Internationally
A long-awaited phase III clinical trial of a novel gene therapy could change malignant pleural mesothelioma treatment in the future. The trial, which will include almost 50 locations around the world, opens this month for mesothelioma patients whose standard treatment has stopped working. The gene therapy drug, called TR002, is also a form of immunotherapy. It will be used in combination with gemcitabine chemotherapy in a second-line setting. “We can’t predict what the outcome will be, but we’re very excited about the potential of this treatment, and the fact there may be another drug in the armamentarium...
Source: Asbestos and Mesothelioma News - April 8, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Mesothelioma Tissue Bank Identifies Survival Factors
This study was on the exploration of risk factors affecting mortality.” The Lancet Respiratory Medicine published the findings early in 2019. Factors Associated with Longer Survival Age under 45 years when diagnosed Female gender Peritoneal mesothelioma subtype Epithelioid histology subtype Treatment including surgery and chemotherapy Stage 1 at time of diagnosis “The identification of these factors could help patients at risk for therapy failure who may benefit from novel interventions, or avoiding treatments that are not effective, or with high mortality risk,” the re...
Source: Asbestos and Mesothelioma News - April 2, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Survival Improves for Peritoneal Mesothelioma Patients in Finland
Survival time improved significantly for peritoneal mesothelioma patients in Finland who underwent a combination of surgery and chemotherapy, according to a recently released study. The five-year survival rate was 66 percent. The median survival was 62 months. According to a smaller, previous study in Finland, the median survival without treatment was just four months after diagnosis. “Despite these advances in treatment…the majority of patients with malignant peritoneal mesothelioma receive only palliative care of systemic chemotherapy, leaving many eligible patients without the benefit of this more invasive...
Source: Asbestos and Mesothelioma News - April 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Better Muscle Mass Linked to Improved Immunotherapy Response
Researchers at Osaka University in Japan have identified a key component of physical health associated with response to immunotherapy drugs. Among people with non-small cell lung cancer, higher levels of muscle mass predicted a better response to PD-1 inhibitor immunotherapy. Sarcopenia — the term used to describe low muscle mass levels — appears to reduce the benefits a person receives from immunotherapy cancer treatment. “Sarcopenia at baseline is a significant predictor of worse outcome in patients with advanced NSCLC [non-small cell lung cancer] receiving PD-1 blockade,” the study investigators ...
Source: Asbestos and Mesothelioma News - March 28, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

US Geological Survey: 750 Metric Tons of Asbestos Imported in 2018
The United States imported an estimated 750 metric tons of raw asbestos in 2018, more than double the total in 2017 and the most entering the country since 2013, according to the recently released U.S. Geological Survey Mineral Commodity Summaries report. For the first time, all of the imported asbestos went to the chloralkali industry, which uses it to manufacture semipermeable diaphragms to make chlorine. The report was prepared by Daniel Flanagan, a mineral commodity specialist for the National Minerals Information Center at the U.S. Geological Survey. It is part of the U.S. Department of the Interior. Asbestos consume...
Source: Asbestos and Mesothelioma News - March 26, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Pacific Mesothelioma Center Moves Closer to Treatment Breakthrough
Thoracic surgeon Dr. Robert Cameron and the Pacific Mesothelioma Center moved closer to a major treatment advance by obtaining U.S. patent approval for their novel mesenchymal stem cell research program. The patent approval in February makes the research program more attractive to potential investors who could accelerate development and change the way malignant mesothelioma is treated. “This is a big deal in the developmental path for MSC [mesenchymal stem cell] therapy,” Patent Adviser Dr. Walid Sabbagh told The Mesothelioma Center at Asbestos.com. “The patent is a pathway to really help these cancer pat...
Source: Asbestos and Mesothelioma News - March 25, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Supreme Court Rules to Protect Navy Veterans in Asbestos Case
The U.S. Supreme Court ruled Tuesday that manufacturers are liable for asbestos-containing materials they did not make, distribute or install, but were needed for their equipment to function properly. The maritime-law ruling involved Navy veterans who were not warned about the danger of asbestos insulation added by a third party to pumps, turbines and blowers aboard three different ships. The ruling will allow cases filed originally by Navy veterans Kenneth McAfee and John DeVries to move forward against five manufacturers. Both veterans died from cancer during the course of litigation. The deaths have been attributed to a...
Source: Asbestos and Mesothelioma News - March 20, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

US Launches First National Firefighter Cancer Registry
The National Institute for Occupational Safety and Health has launched the first nationwide Firefighter Cancer Registry, linking workplace exposures to deadly malignancies such as mesothelioma. Officials administering the study believe the registry will help reduce the incidence of various cancers for firefighters. “A national registry will go a long way toward answering the many questions still out there,” Dr. Kenny Fent, an industrial hygienist at NIOSH who is leading the effort, told The Mesothelioma Center at Asbestos.com. “We’re just laying the groundwork now, but in the long run, we want to h...
Source: Asbestos and Mesothelioma News - March 18, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study: Less-Invasive Mesothelioma Surgery Yields Better Results
A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower ...
Source: Asbestos and Mesothelioma News - March 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Treatment Combines Proton and Photodynamic Therapy
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in ...
Source: Asbestos and Mesothelioma News - March 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA: Asbestos Confirmed in Children ’ s Makeup
The U.S. Food and Drug Administration on Tuesday confirmed the 2017 finding of asbestos contamination in children’s cosmetic products sold by retailers Claire’s and Justice. FDA Commissioner Scott Gottlieb and Susan Mayne, director of the Center for Food Safety and Applied Nutrition, released a joint statement announcing the results of independent tests that confirmed asbestos contamination in three of the product samples from Claire’s and one of the samples from Justice. Asbestos is a naturally occurring mineral often found near talc, a key ingredient in many cosmetic products. Exposure to asbestos can...
Source: Asbestos and Mesothelioma News - March 5, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Targeting Blood-Clotting Pathway Improves Mesothelioma Treatment
A team of researchers at the Cancer and Vascular Biology Research Center in Haifa, Israel, and the Langone Medical Center in New York collaborated on research of a common blood-clotting pathway. Targeting this pathway may offer a unique avenue for improving existing mesothelioma treatments. Researchers said the standard first-line chemotherapy for malignant pleural mesothelioma — a combination of Alimta (pemetrexed) and cisplatin — offers little benefit to most mesothelioma patients. “This treatment regimen confers a median progression-free survival of 5.7 months,” according to the study published ...
Source: Asbestos and Mesothelioma News - March 5, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Belgian EPP Study Shows Mesothelioma Surgery Extends Survival
Using proper patient selection, doctors in Leuven, Belgium, are extending mesothelioma survival times significantly with the controversial extrapleural pneumonectomy surgery. Despite a growing reluctance to perform the surgery within the United States and throughout much of Europe, mesothelioma specialists at University Hospitals KU Leuven have continued performing it with great success. Their 2018 single-center study of the extrapleural pneumonectomy (EPP) for pleural mesothelioma produced a 33.2-month median survival and a 24.2 percent five-year survival. “With our dedicated team, a patient can do well with this su...
Source: Asbestos and Mesothelioma News - March 4, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Targeting Certain Lymph Nodes Could Change Mesothelioma Treatment
Thoracic surgeon Dr. Joseph Friedberg at the University of Maryland School of Medicine has identified previously underutilized lymph nodes that could change the way pleural mesothelioma is diagnosed, staged and treated. Friedberg is the head of the Division of Thoracic surgery at Maryland and director of the Mesothelioma and Thoracic Oncology Treatment and Research Center. The findings are based upon the posterior intercostal lymph nodes — a part of the lymphatic system between the ribs near the spine — in 56 mesothelioma patients who were part of a recent clinical trial. Friedberg detailed the groundbreaking f...
Source: Asbestos and Mesothelioma News - February 26, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J Faces Federal Subpoenas on Asbestos in Its Baby Powder
Johnson & Johnson executives this week revealed the Department of Justice and the Securities and Exchange Commission issued subpoenas related to ongoing lawsuits over the company’s alleged asbestos contamination in its popular talcum powder. The company disclosed the federal inquiries in its annual report to the SEC on Wednesday. It was the first time the pharmaceutical giant admitted that federal agencies had subpoenaed the company about its talc products. Despite thousands of lawsuits and a 2017 report that showed J&J executives were aware of the asbestos liabilities since the 1970s, company officials deny ...
Source: Asbestos and Mesothelioma News - February 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Immunotherapy Clinical Trial Targets Common Mesothelioma Protein
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - February 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Dr. Mags Portman, HIV Prevention Pioneer, Dies from Mesothelioma at 44
Dr. Mags Portman, a British trailblazer in the fight to prevent and control HIV, died Wednesday after a two-year battle with mesothelioma. She was 44. Portman was lauded for triggering a significant reduction in HIV diagnoses throughout the United Kingdom by her work as a researcher, clinician and outspoken advocate. She earned international acclaim for her work as an HIV consultant at London’s Mortimer Market Centre, a progressive sexual health clinic that made pre-exposure prophylaxis (PrEP) a reality in the U.K. Portman played a key role in the 2014 study at The Royal London Hospital that proved the efficacy of t...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J Talc Supplier Imerys Files for Bankruptcy Over Cancer Lawsuits
Seeking protection from rapidly mounting litigation, Imerys Talc America and two of its subsidiaries filed for Chapter 11 bankruptcy protection Wednesday in Delaware. Imerys is a major talc supplier for Johnson & Johnson consumer goods, including the company’s iconic baby powder and Shower to Shower line. Litigants claim the talc-based products were contaminated with asbestos, leading to cases of mesothelioma and ovarian cancer. The bankruptcy filing comes in the midst of an ongoing, high-profile trial in California in which a woman is blaming Imerys talc for her mesothelioma, a rare cancer caused almost exclus...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Chemo-Carrying Gold Nanoparticles Tested on Mesothelioma
Italian researchers have found early success using gold nanoparticles as a chemotherapy-delivery vehicle for mesothelioma. They are hopeful their discovery will lead to an improvement in mesothelioma treatment in the future. The researchers tested their strategy on pleural mesothelioma cells in the lab. They first designed gold nanoparticles with a specific antibody targeted to the cells. Then they loaded the chemotherapy drug Alimta (pemetrexed) into the nanoparticles and observed its effect on the cancer cells. Delivering Alimta through the gold nanoparticles proved more effective than standard chemotherapy. But the me...
Source: Asbestos and Mesothelioma News - February 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Immunotherapy Combination Gaining Momentum
Recent studies from France and the Netherlands have shown patients with pleural mesothelioma can benefit significantly from a second-line immunotherapy drug combination. In separate phase II studies, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) created a synergy that helped stop or slow tumor growth after traditional chemotherapy had failed. “Our results add to the growing evidence that immunotherapy is a promising treatment,” wrote lead author Dr. Maria Disselhorst of the Netherlands Cancer Institute in Amsterdam. “The combination of nivolumab plus ipilimumab showed marked efficacy in pa...
Source: Asbestos and Mesothelioma News - February 11, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

State Attorneys General Push for Tougher Asbestos Reporting Rule
A coalition of 15 attorneys general are calling for a tougher asbestos reporting rule as part of the recently-revised Toxic Substances Control Act. Maine’s newly elected Attorney General Aaron Frey said last week the coalition wants to eliminate the exemptions for asbestos within the current Chemical Data Reporting guidelines. The attorneys general have asked U.S. Environmental Protection Agency Acting Administrator Andrew Wheeler to initiate a new rulemaking process, helping it comply with their interpretation of the legislation. “This [new] rule would allow the EPA to comply with the Act by giving it the info...
Source: Asbestos and Mesothelioma News - February 6, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Senator Probing Johnson & Johnson About Asbestos in Talc
Sen. Patty Murray, D-Wash., has questions, and she wants answers from Johnson & Johnson about its iconic baby powder and the reported link to asbestos-related cancers. Murray recently sent a letter to Johnson & Johnson CEO Alex Gorsky, asking for documentation about past testing for asbestos-tainted talc and communication with the FDA regarding the safety of its product. Murray is a ranking member of the Senate Committee on Health, Education, Labor and Pensions. The letter stemmed from an earlier report by Reuters that Johnson & Johnson hid evidence of asbestos in its product for many years and intentionally mi...
Source: Asbestos and Mesothelioma News - February 4, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Apatinib Case Study Uncovers Potential Mesothelioma Treatment
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - January 31, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Gene-Editing Tool Reverses Cancer Resistance to Chemotherapy
A team of researchers at the Gene Editing Institute in Newark, Delaware, has successfully treated chemotherapy-resistant lung cancer cells with the CRISPR gene-editing technique. The study was published Dec. 21, 2018, in Molecular Therapy Oncolytics. In addition to making drug-resistant lung cancer cells treatable with chemotherapy, the approach offers the potential to improve quality of life for cancer patients. “In the broader sense, such an approach would ultimately lead to a reduced level of chemotherapy required to produce the same tumor-killing activity, leading to an improvement in the quality of life of a can...
Source: Asbestos and Mesothelioma News - January 28, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Vaccine and Chemotherapy Combo Shows Promise for Mesothelioma
Mesothelioma patients showed an impressive immune response to TroVax, a novel cancer vaccine, when it was combined with standard chemotherapy in a recent clinical trial. Researchers from Cardiff University in the United Kingdom conducted the study that was published by the journal OncoImmunology. TroVax is a laboratory engineered virus designed to target the human protein 5T4. A mutated form of 5T4 is found in almost all mesothelioma tumors, including the sarcomatoid subtype, the most difficult to treat. The phase II clinical trial produced a disease control rate of 87 percent, more than double the rate of a previous stud...
Source: Asbestos and Mesothelioma News - January 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Researchers Seek More Effectiveness from Immunotherapy
The objective-response rate was 9 percent, which included one patient with a complete response and disappearance of all tumor burden, and four patients with a partial response. Of the 48 patients whose data were assessed for change in tumor size, 24 experienced a reduction of some level. Most encouraging were the patients with a higher-level of PD-L1. They had a median overall survival of 20.2 months and a 12-month overall survival of 72.5 percent. PD-L1 presence alone, though, is not considered the only factor in how well the drug would work. Other factors such as genetic mutations of the tumor and mesothelioma cell type ...
Source: Asbestos and Mesothelioma News - January 17, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Congress Funds Feasibility Study for Mesothelioma Patient Registry
The National Institute for Occupational Safety and Health will oversee a study in 2019 to determine the feasibility of establishing the first national mesothelioma patient registry. The $100,000 feasibility study was part of the $1.2 million Congress allocated in 2019 to the Centers of Disease Control and Prevention for mesothelioma research. The bulk of the funding goes toward the National Mesothelioma Virtual Bank, which is a biospecimen registry first established in 2006. It is the only federally funded program designed exclusively for the research of mesothelioma, the rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - January 15, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Symposium Brings Specialists and Survivors Together
Some of the nation’s top mesothelioma specialists are scheduled to share their expertise at the 2019 International Symposium on Malignant Mesothelioma. The event, organized by the Mesothelioma Applied Research Foundation, will be held March 24-27 in Bethesda, Maryland. The three-day symposium consists of two days of conference sessions and an advocacy day March 27. Mesothelioma patients, caregivers, family members and the bereaved community are invited to attend and learn about the latest treatment options for this rare cancer. “The symposium is a unique event for mesothelioma patients, their families and careg...
Source: Asbestos and Mesothelioma News - January 9, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Debate Continues on When Best to Use Mesothelioma Chemotherapy
This study is pretty reassuring that half the patients aren’t getting a more optimal or superior approach,” Simone said. “Both are good, accepted approaches. It’s more what the institution is comfortable with, and how the doctors are trained to do it.” European Trial May Be More Definitive The ongoing clinical trial is being done at centers in Belgium, France and the Netherlands. The European Organization for Research and Treatment of Cancer is sponsoring the study. The goal is 64 patients, half of whom will undergo pleurectomy and decortication surgery followed by three cycles of pemetrexed a...
Source: Asbestos and Mesothelioma News - January 3, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Top 10 Mesothelioma and Asbestos News Stories of 2018
The death of renowned thoracic surgeon Dr. David Sugarbaker stunned the mesothelioma community, while asbestos awareness reached new heights in 2018. The loss of Sugarbaker, who pioneered mesothelioma treatment advances through three decades, was devastating to so many that he touched. On the other side, companies that continue to ignore the dangers of toxic asbestos were exposed — in the courtroom and in news coverage — about the problems they caused. Toxic asbestos was found in cosmetics, crayons and on the hands of executives at Johnson & Johnson, which is already paying the price. Here are the 10 most c...
Source: Asbestos and Mesothelioma News - December 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Documentary About Mesothelioma and Asbestos Exposure Now Streaming
The 2018 documentary “Dirty Laundry” is now available for the world to see. In the film, cousins Conor B. Lewis and Zack Johnson cycle more than 4,000 miles from California to New York, fueled by curiosity about their beloved grandmother’s surprise death to mesothelioma. Lewis and Johnson scour the country in search of others affected by this rare cancer caused by asbestos exposure, interviewing surviving family members, doctors, activists and residents living in Libby, Montana, and Ambler, Pennsylvania — two infamous EPA Superfund sites for asbestos cleanup. The film uncovers the harsh reality tha...
Source: Asbestos and Mesothelioma News - December 19, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Clinical Trial Tests CAR T-Cell Therapy on Peritoneal Mesothelioma
The National Cancer Institute in Rockville, Maryland, has opened an innovative clinical trial for patients with peritoneal mesothelioma that will explore the safety and effectiveness of a novel CAR T-cell therapy. The phase I trial also is being conducted at Washington University in St. Louis. It is aimed at patients whose disease has relapsed after initial chemotherapy treatment. It involves a laboratory modification of a patient’s T cells — a type of white blood cell — that can help the immune system kill the cancer. CAR T-cell therapy is a form of gene therapy that has been highly successful with blood...
Source: Asbestos and Mesothelioma News - December 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Johnson & Johnson Knew of Asbestos in Baby Powder for Decades
Investors responded negatively to an extensive report Friday that Johnson & Johnson knew for decades that its iconic baby powder could be contaminated with asbestos fibers but failed to warn the public or inform regulators. Shares of Johnson & Johnson stock dropped by 10 percent Friday, its worst loss in almost two decades, dealing the company a serious financial setback. Reuters News Service detailed internal documents, company memos and extensive conversations that contradicted previous claims by Johnson & Johnson that its Shower to Shower and Baby Powder products were beyond reproach. Johnson & Johnson a...
Source: Asbestos and Mesothelioma News - December 14, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Johnson & Johnson Knew of Asbestos in Talc for Decades
Investors responded negatively to an extensive report Friday that Johnson & Johnson knew for decades that its iconic baby powder could be contaminated with asbestos fibers but failed to warn the public or inform regulators. Shares of Johnson & Johnson stock dropped by 10 percent Friday, its worst loss in almost two decades, dealing the company a serious financial setback. Reuters News Service detailed internal documents, company memos and extensive conversations that contradicted previous claims by Johnson & Johnson that its Shower to Shower and Baby Powder products were beyond reproach. Johnson & Johnson a...
Source: Asbestos and Mesothelioma News - December 14, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Cancer Incidence Rising Rapidly Around the World
More than 30,000 people around the world will be diagnosed with malignant mesothelioma cancer in 2018, according to the latest estimates by the International Agency for Research on Cancer. Almost 26,000 will die from the disease. The numbers on mesothelioma were part of a larger report that included 36 types of cancer. The research covered 185 countries throughout 20 regions. It was published in the November/December issue of CA: A Cancer Journal for Clinicians. An estimated 18.1 million new cancer cases and 9.6 million cancer deaths are expected in 2018, a significant rise from 2012, when the agency published its last stu...
Source: Asbestos and Mesothelioma News - December 13, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Bittersweet Ending to Asbestos Cleanup in Libby, Montana
The asbestos cleanup of Libby, Montana, is coming to a celebrated close. The U.S. Environmental Protection Agency will soon end the largest, longest-running asbestos cleanup project in American history. It’s a bittersweet ending to what is left behind. The 19-year, $600 million EPA Superfund project aimed to right the wrongs created by the shuttered W.R. Grace and Co. vermiculite mine. Once the lifeblood of the community, it also became a cold-hearted killer. Although the mine was closed almost 30 years ago, health officials have since documented more than 400 deaths linked to asbestos-related diseases such as mes...
Source: Asbestos and Mesothelioma News - December 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news